Capricor Therapeutics (NASDAQ:CAPR) Cut to "Sell" at Wall Street Zen

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Thursday.

CAPR has been the topic of several other reports. Roth Capital started coverage on shares of Capricor Therapeutics in a report on Tuesday. They issued a "buy" rating and a $31.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Monday, March 17th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $35.50.

Capricor Therapeutics Price Performance

NASDAQ CAPR traded down $0.28 on Thursday, hitting $10.84. 479,119 shares of the stock were exchanged, compared to its average volume of 1,712,153. The company has a market capitalization of $495.28 million, a PE ratio of -10.27 and a beta of 0.85. The business's fifty day moving average is $10.57 and its 200 day moving average is $13.57. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The firm had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. During the same quarter in the prior year, the firm earned ($0.31) earnings per share. Analysts predict that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently modified their holdings of CAPR. Summit Investment Advisors Inc. raised its stake in Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 2,947 shares during the period. Virtus ETF Advisers LLC bought a new position in shares of Capricor Therapeutics during the fourth quarter worth approximately $68,000. AlphaQuest LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund raised its position in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after buying an additional 5,000 shares in the last quarter. Institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.